FDA fast-tracks AbbVie’s spinal injury drugThe FDA has fast tracked development of AbbVie’s potential spinal injury drug, elezanumab, a process that will be Share XFDA fast-tracks AbbVie’s spinal injury drughttps://pharmaphorum.com/news/fda-fast-tracks-abbvies-spinal-injury-drug/
